Last reviewed · How we verify
NCT06560086
Ketoconazole Contributes to Cryptorchidism Outcome Via Modulating Macrophage Trem2
NA trial testing Ketoconazole in Cryptorchidism in 10 participants. Status unknown.
1 December 2024
Quick facts
| Lead sponsor | Affiliated Hospital of Nantong University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 10 |
| Start date | 3 February 2024 |
| Primary completion | 1 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Ketoconazole (ketoconazole) — full drug profile →
- Luteinizing Hormone (Luteinizing Hormone) — full drug profile →
Conditions studied
- Cryptorchidism — all drugs for Cryptorchidism →
Sponsor
Affiliated Hospital of Nantong University
Who can join
Adults 8 Weeks to 13 Weeks, male only, with Cryptorchidism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Reduced hormone insulin-like 3, exclusively secreted by Leydig cells, has been identified as the recognized mechanism for cryptorchidism. Testicular macrophages residing in the testicular interstitium were thought to play a vital role in maintaining hormone secretion of Leydig cells. However, the contribution of macrophages to cryptorchidism remained poorly understood. Here, after 14 days of ketoconazole treatment, levels of both Trem2 and insulin-like 3 significantly decrease in human embryonic testes compared to the untreated control group. Conversely, 14 days of luteinizing hormone stimulation lead to elevated levels of Trem2 and insulin-like 3 in the testes compared to the untreated control group. Additionally, researchers find a positive correlation between Trem2 and insulin-like 3 expression in a human ex vivo tissue culture model. In summary, the study will propose Trem2 as a novel target for maintaining normal testicular descent by regulating the testicular immune microenvironment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06560086
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ketoconazole
Trials testing the same drug.
- NCT04869449 — Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas · EARLY_PHASE1 · terminated
- NCT04212000 — Bioavailability of Levoketoconazole and Ketoconazole Tablets · Phase 1 · completed
- NCT03796273 — Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases · EARLY_PHASE1 · terminated
- NCT03471364 — Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash · EARLY_PHASE1 · completed
- NCT03473418 — Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis · Phase 3 · unknown
Other recruiting trials for Cryptorchidism
Currently open trials in the same condition.
- NCT07426796 — Comparison of Posterior QLB and QIPB in Pediatric Undescended Testis Surgery. · NA · recruiting
- NCT06558994 — Transection Versus Ligation of Internal Spermatic Vessels in Laparoscopic Fowler-Stephens Orchidopexy · NA · recruiting
- NCT04342026 — Role of the Environment and Endocrine Disruptors in Child Cryptorchidism · recruiting
Other Affiliated Hospital of Nantong University trials
Trials by the same sponsor.
- NCT07506668 — RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas · Phase 1, PHASE2 · not yet recruiting
- NCT07342283 — QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer · Phase 2 · recruiting
- NCT07382453 — Effect of PAE Hydrogel Loaded With tRF-ASO-Exo on Patients With Diabetic Ocular Surface Diseases · Phase 2 · not yet recruiting
- NCT07247838 — Prospective Cohort Control Study on Changes in Gut Microbiota in Ischemic Stroke · recruiting
- NCT07271147 — Effects of taVNS Combined With Dexmedetomidine on POVN · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06560086 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital of Nantong University
- Last refreshed: 19 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06560086.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing